It was a happy coincidence: the final text of the Recommendations of the Multidisciplinary and Multiprofessional Working Group on the Clinical Use of Psychedelic Substances was released on the same day that the Portuguese National Health System announced its decision to fully reimburse the treatment of resistant depression with a substance called esketamine.

[PLEASE NOTE THAT THE RECRUITMENT PROCESS FOR THIS CALL IS NOW CLOSED]

Position overview

We are seeking a highly motivated and skilled Post-Doctoral Fellow to join our dynamic research team at the Botton-Champalimaud Pancreatic Cancer Centre. This prestigious center is dedicated to advancing pancreatic cancer research and treatment through innovative approaches and multidisciplinary collaboration.

Analysing these scans can also be time-consuming and complex, as doctors need to pore over countless images, looking for often tiny details.

So, any new imaging analysis technique that is faster and more precise is always welcome: a new paper (recently published in the Journal of Nuclear Medicine) reveals that the Champalimaud Foundation’s Nuclear Medicine-Radiopharmacology Unit has managed just that by using Deep Learning (DL) Artificial Intelligence (AI).

On the upcoming May 12th at 5:30 PM, the Auditorium of the Champalimaud Foundation will host a landmark event: the public presentation of the Multidisciplinary Recommendations on the Clinical Use of Psychedelic Substances.

The conference Moving Beyond, which took place at the Champalimaud Foundation on April 3 and 4, 2025, was organised to gather world scientific leaders in the field of “exercise oncology”.

During the two-day conference, we interviewed a series of invited speakers on the benefits of physical activity for cancer prevention and treatment and asked speakers to share some of the key scientific advances in exercise oncology.

Watch the video and hear what they had to say — we hope you enjoy it!

At the Champalimaud Colorectal Cancer Conference, last February, Gina Brown, from the Imperial College London, questioned the validity of the current staging strategy for colon cancer. Indeed, research shows that lymph nodes are not the main culprit in colon cancer spread, and can actually be a sign that the patient’s immune system is fighting back. 

Coordinated by Professor Ana Santos Almeida, principal investigator of a translational laboratory at the GIMM Foundation - Gulbenkian Institute for Molecular Medicine (GIMM-CARE), this study will take place at the Champalimaud Foundation, in collaboration with Dr. José Azevedo, surgeon of the Colorectal Cancer Group of the Digestive Unit of the Champalimaud Clinical Center, and at the Hospital de Santa Maria, with the participation of oncologists Professor Luís Costa and Dr. André Mansinho.